PURPOSE: The purpose of this study is to verify that there is a cluster of symptoms in women with breast cancer who were treated with curative intent and are free of disease. METHODS: One hundred and thirty-eight patients were recruited from the Mastology Department of Hospital A.C. Camargo with breast cancer, who have been treated with curative intent and concluded adjuvant chemotherapy 3-24 months prior who may or may not be using hormone therapy. The characterization of the sample was made through descriptive statistics (mean, standard deviation, median, and percentage). For evaluation of the cluster of symptoms, the following were used: Pearson correlation coefficient among the scales of Profile of Mood States, EORTC-QLQ-C30, and EORTC-BR23 and a factor analysis with principal components analysis with promax rotation (oblique). For the extraction of factors, an eigenvalue of 1 was considered, and to evaluate the permanence of symptom factor, a load greater than 0.40 was considered. Statistical significance was defined as p value <0.05. RESULTS: Through factor analysis of data, three distinct groupings were observed. Factor 1 corresponds to the psychoemotional symptoms and grouped as depression, confusion, anger, tension, fatigue, and breast symptoms. Factor 2 corresponds to physical symptoms, which include pain, dyspnea, arm symptoms, and insomnia. Finally, factor 3 corresponds to gastrointestinal symptoms (inappetence, diarrhea, nausea, and vomiting). CONCLUSIONS: Through the data presented, the cluster of symptoms could be verified in women with breast cancer who were treated with curative intent and free of disease.
PURPOSE: The purpose of this study is to verify that there is a cluster of symptoms in women with breast cancer who were treated with curative intent and are free of disease. METHODS: One hundred and thirty-eight patients were recruited from the Mastology Department of Hospital A.C. Camargo with breast cancer, who have been treated with curative intent and concluded adjuvant chemotherapy 3-24 months prior who may or may not be using hormone therapy. The characterization of the sample was made through descriptive statistics (mean, standard deviation, median, and percentage). For evaluation of the cluster of symptoms, the following were used: Pearson correlation coefficient among the scales of Profile of Mood States, EORTC-QLQ-C30, and EORTC-BR23 and a factor analysis with principal components analysis with promax rotation (oblique). For the extraction of factors, an eigenvalue of 1 was considered, and to evaluate the permanence of symptom factor, a load greater than 0.40 was considered. Statistical significance was defined as p value <0.05. RESULTS: Through factor analysis of data, three distinct groupings were observed. Factor 1 corresponds to the psychoemotional symptoms and grouped as depression, confusion, anger, tension, fatigue, and breast symptoms. Factor 2 corresponds to physical symptoms, which include pain, dyspnea, arm symptoms, and insomnia. Finally, factor 3 corresponds to gastrointestinal symptoms (inappetence, diarrhea, nausea, and vomiting). CONCLUSIONS: Through the data presented, the cluster of symptoms could be verified in women with breast cancer who were treated with curative intent and free of disease.
Authors: M A Sprangers; M Groenvold; J I Arraras; J Franklin; A te Velde; M Muller; L Franzini; A Williams; H C de Haes; P Hopwood; A Cull; N K Aaronson Journal: J Clin Oncol Date: 1996-10 Impact factor: 44.544
Authors: T Okuyama; T Akechi; A Kugaya; H Okamura; S Imoto; T Nakano; I Mikami; T Hosaka; Y Uchitomi Journal: Support Care Cancer Date: 2000-05 Impact factor: 3.603
Authors: Karen O Anderson; Carl J Getto; Tito R Mendoza; Stephen N Palmer; Xin Shelley Wang; Cielito C Reyes-Gibby; Charles S Cleeland Journal: J Pain Symptom Manage Date: 2003-04 Impact factor: 3.612
Authors: Roberta De Angelis; Andrea Tavilla; Arduino Verdecchia; Steve Scoppa; Mark Hachey; Eric J Feuer; Angela B Mariotto Journal: Cancer Date: 2009-05-01 Impact factor: 6.860
Authors: Laura S Castro; Tracy A Balboni; Talita C Lobo; Rita Simone L Moreira; Harold G Koenig; John R Peteet; Fatima Cintra Journal: J Relig Health Date: 2021-03-12
Authors: Carlo Pirri; Evan Bayliss; James Trotter; Ian N Olver; Paul Katris; Peter Drummond; Robert Bennett Journal: Support Care Cancer Date: 2012-09-14 Impact factor: 3.603
Authors: Melissa Mazor; Janine K Cataldo; Kathryn Lee; Anand Dhruva; Bruce Cooper; Steven M Paul; Kimberly Topp; Betty J Smoot; Laura B Dunn; Jon D Levine; Yvette P Conley; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2017-12-19 Impact factor: 2.398
Authors: Julie L Otte; Janet S Carpenter; Shalini Manchanda; Kevin L Rand; Todd C Skaar; Michael Weaver; Yelena Chernyak; Xin Zhong; Christele Igega; Carol Landis Journal: Cancer Med Date: 2014-11-30 Impact factor: 4.452
Authors: Winnie K W So; Bernard M H Law; Marques S N Ng; Xiaole He; Dorothy N S Chan; Carmen W H Chan; Alexandra L McCarthy Journal: Cancer Med Date: 2021-03-21 Impact factor: 4.452